US$ 29.22
glp-1 drugs contraindications Consensus Recommendations on RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force | Diabetes Therapy contraindication for glp 1 Weight
Description
A patient with significant metabolic dysfunction might benefit from standard-dose semaglutide or tirzepatide's stronger appetite suppression
These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids

Rather than the active compound being a peptide, it is instead a "small molecule", meaning it can withstand the harsh environment of the digestive system and is much cheaper to make and store

In cellular models, the product significantly enhanced GLP-1 secretion by up to 3.27 times compared to untreated groups
Moreover, the decrease in hippocampal volume is significantly related to the total duration of depressive episodes (Sheline et al., 1999)

Physiological Reports